Results 1 to 10 of about 106,038 (228)

Tocilizumab [PDF]

Reactions Weekly, 2020

  +8 more sources

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

Critical Care Explorations, 2021
Objectives:. The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-
Prabalini Rajendram, MD, Gretchen L. Sacha, PharmD, Omar Mehkri, MD, Xiaofeng Wang, PhD, Xiaozhen Han, MS, Vidula Vachharajani, MD, Abhijit Duggal, MD   +6 more
doaj   +2 more sources

Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab. [PDF]

Rheumatology (Oxford)
Suzuki K, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T, Kaneko Y.   +9 more
europepmc   +2 more sources

Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review: 1 approved, 2 approved with reservations]

F1000Research, 2021
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia.
Cahyo Wibisono Nugroho, Satriyo Dwi Suryantoro, Yuliasih Yuliasih, Alfian Nur Rosyid, Tri Pudy Asmarawati, Lucky Andrianto, Herley Windo Setiawan, Bagus Aulia Mahdi, Choirina Windradi, Esthiningrum Dewi Agustin, Jonny Karunia Fajar   +10 more
doaj   +1 more source

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis

Journal of Ophthalmic Inflammation and Infection, 2023
Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Mathilde Leclercq, Paul Goupillou, Hélène Gomez, Marc Muraine, Ygal Benhamou, Nicolas Girszyn, Julie Gueudry   +6 more
doaj   +1 more source

Tocilizumab (Actemra) [PDF]

Human Vaccines & Immunotherapeutics, 2017
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA).
Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi, Bhaskar Dasgupta   +4 more
openaire   +3 more sources

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

International Journal of Infectious Diseases, 2021
Objective: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity.
Edmund Huang, Sharon Isonaka, Haoshu Yang, Erin Salce, Elisa Rosales, Stanley C. Jordan   +5 more
doaj   +1 more source

Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19

BMJ Open, 2022
Objectives Assess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19 pneumonia.Design Retrospective cohort study.Setting Large integrated health system with 9 million members in ...
Sara Y Tartof, Lei Qian, Liyan Liu, Devin Incerti, Jacek Skarbinski, Laura B Amsden, Bradley K Ackerson, Vennis Hong, Bruce H Fireman, Vincent M Yau, Heidi Fischer, Sally F Shaw   +11 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

EClinicalMedicine, 2020
Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–
Tariq Kewan, Fahrettin Covut, Mohammed J. Al–Jaghbeer, Lori Rose, K.V. Gopalakrishna, Bassel Akbik   +5 more
doaj   +1 more source